AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03482895 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Quantitative analysis of enterohormones, citrulline and ApoB48
Study NCT03482895 — intervention group
Intervention type: BIOLOGICAL
Intervention: Feces sampling
Description: Intestinal absorption assessment
Study NCT02447575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education on Use of MDI
Description: After the subject demonstrated the use of MDI with the electronic flowmeter in place, the intervention was provided- a short verbal education to demonstrate the correct use of MDI.
Study NCT02941354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.
Study NCT01244217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine/Allegra (M016455)
Description: Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral
Study NCT02968680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo SLNB
Study NCT02968680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo sonazoid-enhanced ultrasonography
Study NCT02968680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging.
Study NCT01326000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: standard iv chemotherapy
Study NCT01326000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: standard iv chemotherapy
Study NCT01326000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: 1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
Study NCT01326000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
Study NCT04309903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 \* 10 repetitions, 20 sec of per reps and 10 sec of interval.
Study NCT04309903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 \* 10 repetitions, 20 sec of per reps and 10 sec of interval.
Study NCT01718431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal
Study NCT05740345 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: Metformin
Study NCT00089635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion
Study NCT02787057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: IP vancomycin 1g every 5 days
Study NCT02787057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: IP vancomycin 1g every 5 days
Study NCT01718431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reference meal
Study NCT01171183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: controlled release carvedilol
Description: carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
Study NCT01171183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04260464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: A single dose of 30 mg PF-06700841 will be administered on Day 1
Study NCT00522717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
Study NCT00522717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects receive Usual Care for 8 weeks followed by CBT
Study NCT04578587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MicroFET 2
Description: Lumbar Flexor and Extensor Strength Measurement
Study NCT01726049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
Study NCT01726049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks
Study NCT02989571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous normal saline administered at 250ml/hr
Description: Intravenous normal saline administered at 250ml/hr
Study NCT02989571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline administered at 125ml/hr
Description: Intravenous normal saline administered at 125ml/hr
Study NCT04633954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.15% Oph Soln
Description: One drop of Brimonidine Tartrate 0.15% Oph Soln prior to FLACS
Study NCT04067349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergometry
Description: Patients underwent a preoperative ergometry to assess their physical fitness prior to their planned liver resection.~Bicycle stress testing was performed preoperatively and 1 and 6 months postoperatively.
Study NCT04710186 — intervention group
Intervention type: PROCEDURE
Intervention: arterial reconstructive open surgery
Description: Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, arterial tissues were excised, homogenized using a motor driven homogenizer and total RNA was isolated using Trizol reagent (Invitrogen, Milan, Italy), in accordance with the manufacturer's instructions. The expression of Androgen Receptor (AR), insulin receptor (IR) and the IGF-I receptor (IGF-IR) will be quantified by real-time PCR using platform Quant Studio7 Flex Real-Time PCR System (Thermo Fisher Scientific, Milan, Italy), following the manufacturer's instructions.
Study NCT00542932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Watched Film A (promotional film)~Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home
Study NCT03441945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnetic steering
Description: magnetic steering
Study NCT01324739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human BNP-32
Description: 3pmol/kg/min infusion
Study NCT01324739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: human BNP-32
Description: 3pmol/kg/min infusion
Study NCT02202109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHW and Self-sampling for Cervical Cancer
Description: Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
Study NCT02202109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed Self Sampler
Description: Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
Study NCT00467298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise adherence
Description: The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
Study NCT00467298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management- prevention of illness
Description: Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
Study NCT00467298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management of illness
Description: This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
Study NCT02836262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIT Hip Replacement System
Description: HIT Hip Replacement System
Study NCT00665132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimRouter System
Description: Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
Study NCT04338906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: 400 mg tid, d1-d7
Study NCT04338906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Instead of Camostat Mesilate, tid, d1-d7
Study NCT04338906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400 mg bid on day 1, 200 mg bid d2-d7
Study NCT04338906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 400 mg bid on day 1, 200 mg bid d2-d7
Study NCT02482532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tvs-CTL Vaccine
Description: autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
Study NCT00361036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine fibroid embolization BeadBlock™
Description: Intervention with BeadBlock Microspehere
Study NCT00361036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine fibroid embolization Embosphere®
Description: Embosphere - control arm
Study NCT01955759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone tab 200 mg x 3
Description: starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
Study NCT01955759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg tab x1
Description: starting 7 days before coronary by-pass surgery
Study NCT01955759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: beta blockers Bisoprolol in adjusted dose
Description: starting 7 days befoe coronary by-pass surgery
Study NCT01955759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta blockers Bisoprolol in adjusted dose
Description: starting 7 days befoe coronary by-pass surgery
Study NCT03345147 — intervention group
Intervention type: OTHER
Intervention: High Vitamin A intake
Description: Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
Study NCT03345147 — intervention group
Intervention type: OTHER
Intervention: Normal Vitamin A intake
Description: Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
Study NCT03888222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) .
Study NCT03888222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib Oral Tablet
Description: Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .
Study NCT04256369 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Parenteral Nutrition (PN) Premixed Olimel N9E
Description: Parenteral nutrition
Study NCT04224454 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire was adapted from questionnaires used by the French national agency Institut de Veille Sanitaire to study vaccination coverage and were completed with the assistance of one fellow to limit missing data.
Study NCT01814436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scaffold-free SHED-derived pellet
Description: The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
Study NCT02582398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
Study NCT02582398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Light
Description: The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or >500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
Study NCT02561078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human regular U-500 insulin (CSII)
Description: Administered SC
Study NCT02787057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: oral moxifloxacin 400mg QD
Study NCT02787057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidime
Description: IP ceftazidime 1g QD
Study NCT01524068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Steroid Treatment
Description: One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
Study NCT01524068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The Standard Steroid Treatment, Plasma Exchange and rituximab
Description: The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
Study NCT03759145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Participants use exergame with the therapist in the rehabilitation center. Several games are available, the therapist adjusts the choice of game and level of difficulty according to the participant's abilities and interests.
Study NCT03759145 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: participants continued their planned rehabilitation sessions
Study NCT02468713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combiflex® lipid peri
Description: total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
Study NCT02468713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Winuf® peri
Description: total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
Study NCT00464555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet transplant
Description: Transplantation of pancreatic islet cells
Study NCT02561078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human regular U-500 insulin (MDI)
Description: Administered SC
Study NCT04037345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(low-dose)
Description: A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
Study NCT04037345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(mid-dose)
Description: A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
Study NCT04037345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(high-dose)
Description: A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
Study NCT03893006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Level of vehicle automation
Description: From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.
Study NCT01501292 — intervention group
Intervention type: OTHER
Intervention: Fixation and staining
Description: Fixation and staining by MitiTracker Green FM
Study NCT01501292 — intervention group
Intervention type: OTHER
Intervention: Observation by laser microscopy
Description: Observation with Laser scanning confocal microscopy
Study NCT03787420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication system
Description: We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale.
Study NCT03787420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: communication system
Description: We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale.
Study NCT03484299 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Irreversible Electroporation (IRE)
Description: Non-thermal ablation of tumor
Study NCT03484299 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
Study NCT03484299 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FOLFIRINOX
Description: 25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
Study NCT02459405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIR anastomotic perfusion assessment
Description: Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.
Study NCT02459405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared camera
Description: Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
Study NCT00348868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enhanced behavioral motivation counseling
Study NCT00348868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational counseling
Study NCT00348868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Study NCT05005286 — intervention group
Intervention type: OTHER
Intervention: Past history of vaginal Infections
Description: With or without vaginal infection during pregnancy